Ezra's Notes Checked November 16, 2026
Investor Holdings

By @ezracrangle

← Seth Klarman, latest 13F

Seth Klarman · Q2 2019

Baupost Group

Portfolio at the end of Q2 2019, from the 13F filed August 13, 2019. See the filing on EDGAR ↗

CompanyWeightValueSharesPriceHeld sinceChange
Liberty Global LBTYK · history 10.1% $1.11B 41,937,674 $26.53 Q3 2018 Add 7%
Viasat VSAT · history 10.0% $1.11B 13,732,068 $80.82 Q2 2013 or earlier No change
Fox Corporation FOXA · history 9.1% $1.00B 27,322,720 $36.64 Q1 2019 No change
eBay EBAY · history 8.6% $953.8M 24,146,000 $39.50 Q4 2018 Reduce 18%
Cheniere Energy LNG · history 6.6% $730.6M 10,674,135 $68.45 Q1 2014 Reduce 15%
Allergan AGN · history 5.6% $616.1M 3,679,549 $167.43 Q1 2016 Reduce 23%
Bristol-Myers Squibb BMY · history 5.3% $589.5M 13,000,000 $45.35 Q1 2019 Add 225%
Qorvo QRVO · history 5.2% $578.3M 8,681,181 $66.61 Q1 2017 Reduce 18%
PG&E PCG · history 5.1% $561.5M 24,500,000 $22.92 Q1 2018 No change
CBS CBS · history 4.5% $499.0M 10,000,000 $49.90 Q4 2018 Add 17%
McKesson MCK · history 3.2% $348.7M 2,595,011 $134.39 Q3 2017 Reduce 8%
Synchrony SYF · history 2.9% $321.1M 9,260,557 $34.67 Q3 2016 Reduce 35%
Tesla TSLA.CV · convertible notes · history 2.7% $295.5M 300,000,000 prn Q1 2018 No change
DigitalBridge CLNY · history 2.2% $248.4M 49,687,370 $5.00 Q2 2018 No change
Univar Solutions UNVR · history 1.9% $209.4M 9,500,000 $22.04 Q3 2018 No change
Fox Corporation FOX · history 1.9% $207.5M 5,680,307 $36.53 Q1 2019 No change
Liberty Global LBTYA · history 1.8% $200.8M 7,440,705 $26.99 Q3 2018 Add 50%
Cencora COR · history 1.7% $188.8M 2,214,192 $85.26 Q3 2017 Reduce 8%
Takeda Pharmaceutical TAK · history 1.5% $167.1M 9,438,003 $17.70 Q1 2019 Reduce 12%
Antero Resources AR · history 1.4% $158.1M 28,587,791 $5.53 Q3 2014 No change
Theravance Biopharma TBPH · history 1.4% $152.0M 9,309,168 $16.33 Q2 2014 No change
Nexstar Media Group NXST · history 1.3% $141.2M 1,397,755 $101.00 Q4 2018 Add 40%
Atara Biotherapeutics ATRA · history 1.3% $140.8M 7,000,000 $20.11 Q4 2014 Add 10%
Akebia Therapeutics AKBA · history 1.1% $118.4M 24,471,453 $4.84 Q4 2018 No change
Translate Bio TBIO · history 1.0% $109.4M 8,844,239 $12.37 Q2 2018 Add 36%
XPO XPO · history 0.8% $86.7M 1,500,000 $57.81 Q2 2019 Buy
Veritiv VRTV · history 0.6% $69.2M 3,564,439 $19.42 Q3 2014 No change
Trilogy Metals TMQ · history 0.4% $39.8M 13,641,368 $2.92 Q2 2013 or earlier Add 5%
Sinclair SBGI · history 0.3% $29.5M 549,423 $53.63 Q2 2018 Reduce 81%
Gossamer Bio GOSS · history 0.2% $27.3M 1,267,171 $21.51 Q1 2019 No change
Theravance Biopharma TBPH.CV · convertible notes · history 0.2% $25.7M 30,000,000 prn Q4 2016 No change
Paratek Pharmaceuticals PRTK · history 0.1% $9.6M 2,394,498 $3.99 Q4 2014 No change
32 positions100.0%$11.05B

Weight is the position's share of the total value in this 13F, not of the whole fund. Price is the value divided by the number of shares, so it's the price at the end of the quarter, as the firm reported it. Change compares share counts with Q1 2019, adjusted for stock splits.

Sector weighting

Sector weights in this 13F
Media & telecom38.9%
Health care22.6%
Consumer discretionary11.3%
Energy8.0%
Technology5.2%
Financials & real estate5.2%
Utilities5.1%
Industrials3.3%
Materials0.4%

What changed from Q1 2019

← Q1 2019 Q3 2019 →